London Daily

Focus on the big picture.
Saturday, Aug 23, 2025

Here's what's known about the coronavirus variants

Here's what's known about the coronavirus variants

The US Centers for Disease Control and Prevention said this week it had designated a coronavirus variant first seen in India as a "variant of interest," adding it to the growing collection of viral variants it's keeping an eye on.

Vaccine makers are so worried about the chance new variants will escape the protection offered by immunization that they are already testing booster shots and tweaking their vaccine formulas to specifically target some of the more troubling variants.

And doctors around the world are warning that even more variants will arise as the virus continues to evolve inside the bodies of the tens of millions of people it is infecting.

The CDC has designated three levels of variants: variants of interest, which have the potential to be dangerous but haven't caused much disruption yet; variants of concern, which are more contagious, evade some treatments, cause more severe disease or get past diagnostic tests; and variants of high consequence, which significantly evade the effects of vaccines or treatments.

"Currently there are no SARS-CoV-2 variants that rise to the level of high consequence," CDC says.

Here's what's known about the variants of interest and variants of concern:

Variants of interest


In laboratory tests, all the CDC-designated variants of interest have been found to resist the immune attack in blood taken from people who have recovered from Covid-19, as well as from people who have been vaccinated.

B.1.526 - First seen in New York last November, B.1.526 has what's called a 484 mutation. To understand the variants, it's important first to understand the mutations that characterize them. The E484K mutation is a change in the part of the virus called the spike protein -- that's the knobby structure that sticks out from the surface of the virus. The change, in a region called the receptor binding domain, makes the virus attach more easily to the cells it infects and also makes the virus less recognizable to the immune system.

Tests show it can in theory resist the effects of Eli Lilly's combined monoclonal antibody treatment, although it's not clear if that translates into treatment failure, the CDC says. Regeneron's antibody cocktail treatment for Covid-19 seems to work against it. It has also been shown to resist the immune attack in blood taken from people who have recovered from Covid-19, as well as from people who have been vaccinated. It accounted for just under 9% of samples sequenced in the US as of April 10.

New CDC research published this week shows it's not associated with more severe infection or a greater risk of reinfection.

B.1.526.1 - Also first seen in New York, B.1.526.1 has a different pattern of mutations when compared to the original strain sequenced from China, including one called L452R that seems to help the virus infect cells more easily while at the same time making it harder for antibodies to attack.

B.1.617 - First seen in India in February, this one is sometimes misleadingly called a "double mutant" because it has both an L452R mutation and a 484 mutation -- although not quite the same 484 mutation seen in other worrying variants.

B.1.617.1, B.1.617.2 and B.1.617.3 - These were all first seen in India, and were circulating before B.1.617. They all have the same mutations as B.1.617, plus a few extras.

Although Indian officials have said these new variants are driving the spike in coronavirus cases that is currently overwhelming the country's hospitals, the director of India's National Center for Disease Control, Sujeet Singh, said this week the evidence is lacking. "We have not been able to establish the epidemiological and clinical correlation completely yet," Singh said Wednesday.

British health officials, however, upgraded B.1.617.2 to a variant of concern Friday because of its rapid spread there. "There is currently insufficient evidence to indicate that any of the variants recently detected in India cause more severe disease or render the vaccines currently deployed any less effective," Public Health England said in a statement.

Dr. Chris Whitty, chief medical officer for England, said during a Royal Society webcast Thursday that the B.1.617 variants probably fall in the middle in terms of danger between B.1.1.7, which seems almost fully susceptible to vaccines and treatments, and B.1.351, which has been documented to infect people who recovered from infection with earlier variants of coronavirus, and also to partly evade the protection offered by vaccines.

B.1.525 - First seen in the UK and Nigeria, this one carries the E484K mutation. It's been found in fewer than 1% of samples tested in the United States. That surveillance is incomplete. This week, CDC director Dr. Rochelle Walensky said the United States is now sequencing approximately 8% of the country's roughly 450,000 weekly Covid-19 cases.

P.2 - Circulating in Brazil since last year, this variant also carries the worrying E484K mutation and has not been found widely globally.

Variants of concern


CDC defines these as variants for which there is evidence they are more transmissible, cause more severe disease, fail to respond to treatment, evade immune response or fail to be diagnosed by standard tests.

B.1.1.7 - The B.1.1.7 variant first seen in the UK has been shown to be at least 50% more transmissible and some evidence suggests it may cause more severe disease, although at least one study found no evidence of this. It carries 23 mutations, including one called N501Y that increases transmission.

It accounted for 60% of all samples tested in the US as of April 10, according to CDC. The University of Washington's Institute for Health Metrics and Evaluation estimates it now accounts for virtually all new infections in 23 states.

It's fully susceptible to monoclonal antibody treatments and vaccines.

"We are confident that the vaccines that are least currently available in the UK work against that, for practical purposes," Whitty said.

A team in the Gulf state of Qatar tested the effectiveness of the Pfizer/BioNTech vaccine during a time when Qatar was seeing circulation of the B.1.351 variant first seen in South Africa and the B. 1.1.7 variant first seen in the UK.

"The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% at 14 or more days after the second dose. The effectiveness against any documented infection with the B.1.351 variant was 75%," the researchers wrote in a letter to the New England Journal of Medicine.

B.1.351 - First seen in South Africa, this variant has both the E484K mutation that is linked with immune escape and the N501Y mutation suspected of helping make other variants more contagious. It has been shown to be 50% more transmissible and evades Lilly's dual monoclonal antibody treatment but not others. Blood tests and real-life use both suggest it can infect people who have recovered from coronavirus and also people who have been vaccinated against Covid-19.

Vaccine makers trying to get out ahead of the new variants by developing booster shots have focused on B.1.351, as it's the variant scientists most fear could elude vaccine protection. Moderna said Wednesday that a booster shot of its vaccine revs up the immune response against B.1.351 and another variant, P.1.
The good news is it does not seem to cause more severe disease, as initially feared, said Dr. Salim Abdool Karim, Director of the Center for the AIDS Program of Research in South Africa.

"It turns out in South Africa the evidence we have now is that it is not more severe," he told the Royal Society briefing. It does, however, escape the human immune response to a significant degree. It spread rapidly across South Africa, Karim has reported, accounting for 11% of viruses sequenced in October and 87% of samples sequenced in December.

"If you were infected with the virus before, you are not fully protected this time," Karim said. "About one-half of the individuals who were exposed did get infected again."

P.1 - First seen in Brazil, it also has both the E484K and N501Y mutations, with more than 30 others. It has been demonstrated to evade the effects of Lilly's monoclonal antibody treatment but not one made by Regeneron. Blood tests show it might escape both natural and vaccine-elicited immune responses.

B.1.427 - First seen in California, this one has the L452R mutation. CDC says it's about 20% more transmissible and may partly resist the effects of Lilly's monoclonal antibody treatment. Blood tests suggest it might be able to re-infect people who have been vaccinated against Covid or who have recovered but that has not been demonstrated in real life yet.

B.1.429 -- Another so-called California variant, this one has the L452R mutation along with others and is similar to B.1.427 in other ways. It accounted for 4% of samples sequenced nationally as of April 10.

Last month a team at the University of California, San Francisco did in-depth sequencing of more than 2,000 samples from people who tested positive for coronavirus across California. They found the B.1.427/B.1.429 variants increased from no samples in September to half of all samples taken in January.

They seem to replicate better in the noses of infected people, something that could explain their faster spread, the UCSF team, led by Dr. Charles Chiu, reported in the journal Cell. But they are not as transmissible as the B.1.1.7 variant.

Newsletter

Related Articles

0:00
0:00
Close
Bunkers, Billions and Apocalypse: The Secret Compounds of Zuckerberg and the Tech Giants
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
New York Appeals Court Voids Nearly $500 Million Civil Fraud Penalty Against Trump While Upholding Fraud Liability
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
Child-free hotels spark controversy
North Korea is where this 95-year-old wants to die. South Korea won’t let him go. Is this our ally or a human rights enemy?
Hong Kong Launches Regulatory Regime and Trials for HKD-Backed Stablecoins
China rehearses September 3 Victory Day parade as imagery points to ‘loyal wingman’ FH-97 family presence
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
MSNBC Rebrands as MS NOW Amid Comcast’s Cable Spin-Off
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
Finnish MP Dies by Suicide in Parliament Building
Outrage in the Tennis World After Jannik Sinner’s Withdrawal Storm
William and Kate Are Moving House – and the New Neighbors Were Evicted
Class Action Lawsuit Against Volkswagen: Steering Wheel Switches Cause Accidents
Taylor Swift on the Way to the Super Bowl? All the Clues Stirring Up Fans
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Apple Expands Social Media Presence in China With RedNote Account Ahead of iPhone 17 Launch
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Cambridge Dictionary Adds 'Skibidi,' 'Delulu,' and 'Tradwife' Amid Surge of Online Slang
Bill Barr Testifies No Evidence Implicated Trump in Epstein Case; DOJ Set to Release Records
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
The CEO Who Replaced 80% of Employees for the AI Revolution: "I Would Do It Again"
Emails Worth Billions: How Airlines Generate Huge Profits
Character.ai Bets on Future of AI Companionship
China Ramps Up Tax Crackdown on Overseas Investments
Japanese Office Furniture Maker Expands into Bomb Shelter Market
Intel Shares Surge on Possible U.S. Government Investment
Hurricane Erin Threatens U.S. East Coast with Dangerous Surf
EU Blocks Trade Statement Over Digital Rule Dispute
EU Sends Record Aid as Spain Battles Wildfires
JPMorgan Plans New Canary Wharf Tower
Zelenskyy and his allies say they will press Trump on security guarantees
Beijing is moving into gold and other assets, diversifying away from the dollar
Escalating Clashes in Serbia as Anti-Government Protests Spread Nationwide
The Drought in Britain and the Strange Request from the Government to Delete Old Emails
Category 5 Hurricane in the Caribbean: 'Catastrophic Storm' with Winds of 255 km/h
"No, Thanks": The Mathematical Genius Who Turned Down 1.5 Billion Dollars from Zuckerberg
The surprising hero, the ugly incident, and the criticism despite victory: "Liverpool’s defense exposed in full"
Digital Humans Move Beyond Sci-Fi: From Virtual DJs to AI Customer Agents
YouTube will start using AI to guess your age. If it’s wrong, you’ll have to prove it
×